Altria and NJOY Respond to ITC Initial Determination in Complaint Against NJOY
Last week, the ALJ provided notice of her initial determination supporting JUUL’s allegations in its complaint and recommending an exclusion order that would prohibit the importation of
In
We continue to work to bring this issue to resolution. The parties have engaged with a mediator to attempt to negotiate a resolution of these disputes. In addition, NJOY recently filed Substantial Equivalence (SE) Exemption requests with the FDA to allow NJOY to market an already-developed ACE product with minor modifications that we believe avoid three of the four JUUL patent claims at issue in the case.
ACE is the first pod-based e-vapor product and the only pod-based menthol e-vapor product authorized by the FDA as appropriate for the protection of public health. An exclusion order banning the importation of ACE would severely limit FDA-authorized choices for adults and undermine public health.
Altria’s Profile
We have a leading portfolio of tobacco products for
Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products. In combustibles, we own
Additionally, we have a majority-owned joint venture,
Our equity investments include Anheuser-Busch InBev SA/NV (ABI), the world’s largest brewer, and Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company.
The brand portfolios of our operating companies include Marlboro®, Black & Mild®,
Learn more about
Forward-Looking and Cautionary Statements
This release contains certain forward-looking statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to the status of currently pending litigation and regulatory filings, which are inherently subject to risks and uncertainties, and we cannot predict the timing or outcome of any litigation or regulatory filing. Factors that could cause actual results to differ materially from those contained in, or implied by, the forward-looking statements included in this release include uncertainty and delays with respect to pending or future litigation proceedings and regulatory review timelines, and unfavorable outcomes with respect to such litigation proceedings or regulatory reviews, among others. Other risk factors are detailed from time to time in our publicly filed reports, including our Annual Report on Form 10-K for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827752036/en/
Investor Relations
804-484-8222
Media Relations
804-484-8897
Source: